CAM
CYTK icon

Connacht Asset Management’s Cytokinetics CYTK Stock Holding History

Connacht Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,000
Closed -$339K – 120
2022
Q3 		$339K Buy
+7,000
New +$337K 0.24% 91

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Connacht Asset Management's CYTK Position: Q3 2023 in Review

Connacht Asset Management sold out of Cytokinetics (CYTK) in Q3 2023, closing a stake of 7,238 shares — an estimated $236K sold.

Connacht Asset Management first reported a position in CYTK in Q4 2021 and held it in 7 quarters. The position peaked at $548K in Q4 2021. 250 funds tracked by Wall St. Rank hold CYTK as of Q3 2023.

  • Connacht Asset Management reported no remaining Cytokinetics position as of Q3 2023 after selling out during the quarter.
  • Connacht Asset Management sold 7,238 Cytokinetics shares in Q3 2023, an estimated $236K.
  • Connacht Asset Management first reported a position in Cytokinetics in Q4 2021 and held it in 7 quarters.
  • Connacht Asset Management's Cytokinetics position peaked at $548K in Q4 2021.
  • 250 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.